for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly's antibody combination reduces risk of death from COVID-19 - study

Jan 26 (Reuters) - Eli Lilly and Co said on Tuesday treatment with a combination of two of its antibodies helped reduce risk of hospitalizations and death due to COVID-19 by 70%, according to results from a late-stage trial.

The results are from over 1,000 participants of the study, which is testing the combination of bamlanivimab and etesevimab. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up